BioSpace News Archive

Harmony Biosciences Holdings, Inc. has successfully completed an End-of-Phase 2 meeting with FDA regarding its clinical development plan evaluating pitolisant as a potential treatment for excessive daytime sleepiness (EDS) in patients ages six and older with Prader-Willi syndrome (PWS).

Suono Bio Inc. has released encouraging results from the first in human clinical trial testing its SuonoCalm™ platform.

Quanterix Corporation today announced that it will report financial results for the second quarter 2023 before the market opens on Tuesday, August 8, 2023, and will host a webcast and conference call on the same day at 8:30 a.m. E.T.

GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc (“Parent”).

Twist Bioscience Corporation today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, before the opening of the market on Friday, August 4, 2023.

Pasithea Therapeutics Corp. today announced that its Board of Directors (the “Board”) has authorized the repurchase, through a $4.0 million tender offer (“Tender Offer”), of up to approximately 5.7 million shares.

KromaTiD announced the launch of over 300 centromere, telomere and gene probes for use in directional Genomic Hybridization in-Site™ assays.

Altamira Therapeutics Ltd. announced that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio®, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries.

CytomX Therapeutics, Inc. today announced that on July 19, 2023, the Company granted its recently appointed Senior Vice President, Chief Medical Officer, Yu-Waye (Wayne) Chu, M.D., an option to purchase 375,000 shares of the Company’s common stock and also granted an additional new employee options to purchase 2,500 shares of the Company’s common stock.

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules, is thrilled that – following pre-submission meetings held in Q1 of 2023 – it has received written guidance from the UK’s Medicines and Healthcare products Regulatory Agency’s.